Amyloid-β (Aβ) oligomers are implicated in Alzheimer disease (AD). However, their unstable nature and heterogeneous state disrupts elucidation of their explicit role in AD progression, impeding the development of tools targeting soluble Aβ oligomers. Herein parallel and anti-parallel variants of Aβ(1–40) dimers were designed and synthesized, and their pathogenic properties in AD models characterized. Anti-parallel dimers induced cognitive impairments with increased amyloidogenesis and cytotoxicity, and this dimer was then used in a screening platform. Through screening, two FDA-approved drugs, Oxytetracycline and Sunitinib, were identified to dissociate Aβ oligomers and plaques to monomers in 5XFAD transgenic mice. In addition, fluorescent Astrophloxine was shown to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of AD mice. This screening platform provides a stable and homogeneous environment for observing Aβ interactions with dimer-specific molecules.
|Number of pages||10|
|Journal||Angewandte Chemie - International Edition|
|Publication status||Published - 2020 Jul 6|
Bibliographical noteFunding Information:
All images are created by the authors of this manuscript. All experimental and animal protocols were approved by Yonsei University. This work was supported by Korea Health Industry Development Institute (KHIDI, HI18C0836), National Research Foundation of Korea (NRF‐2018R1A6A1A03023718, NRF‐2018R1D1A1B07048857, and NRF‐2018M3C7A1021858), Yonsei University (2018‐22‐0022), KIST (2Z05620 and 2E29562), and POSCO TJ Foundation (POSCO Science Fellowship).
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
All Science Journal Classification (ASJC) codes